Scapa E, Thomas P, Loewenstein M S, Zamcheck N
Eur J Cancer Clin Oncol. 1985 Sep;21(9):1037-42. doi: 10.1016/0277-5379(85)90287-1.
Fifty-one patients (16 with malignant extrahepatic biliary obstruction, ten with benign extrahepatic biliary obstruction, eight with alcoholic liver disease, five with viral hepatitis and 12 with liver metastases) and 19 adult healthy controls were studied with determinations of beta-N-acetyl hexosaminidase (a lysosomal enzyme which is cleared from the circulation by the Kupffer cells), carcinoembryonic antigen (CEA), serum bilirubin, alkaline-phosphatase and aspartate aminotransferase (AST). Both CEA and beta-NAH were elevated in each disease group. Elevated beta-NAH levels distinguished between benign and malignant extrahepatic biliary obstruction better than CEA levels. Beta-NAH levels for the malignant and the benign groups were 47.6 +/- 14.7 U/l and 23.0 +/- 4.7 U/l (mean +/- S.D.) respectively. The groups differed significantly (P less than 0.001). Plasma CEA levels for both groups were 18.7 +/- 38.9 and 7.2 +/- 3.3 ng/ml (mean +/- S.D.) respectively. Beta-NAH levels for the 19 normal controls were 15.8 +/- 3.5 U/l (mean +/- S.D.). Beta-NAH also was significantly elevated in patients with hepatic metastases (36.9 +/- 20.1 U/l). In 25 cancer patients with metastases other than in the liver beta-NAH levels (18.3 +/- 5.2) were not significantly elevated over the control group. It has potential value as a marker for non-CEA-producing liver metastases.
对51例患者（16例伴有恶性肝外胆管梗阻、10例伴有良性肝外胆管梗阻、8例患有酒精性肝病、5例患有病毒性肝炎以及12例患有肝转移）和19名成年健康对照者进行了研究，测定了β-N-乙酰己糖胺酶（一种溶酶体酶，可被库普弗细胞从循环中清除）、癌胚抗原（CEA）、血清胆红素、碱性磷酸酶和天冬氨酸转氨酶（AST）。每个疾病组中的CEA和β-NAH均升高。β-NAH水平升高在区分良性和恶性肝外胆管梗阻方面比CEA水平更好。恶性组和良性组的β-NAH水平分别为47.6±14.7 U/l和23.0±4.7 U/l（平均值±标准差）。两组差异显著（P<0.001）。两组的血浆CEA水平分别为18.7±38.9和7.2±3.3 ng/ml（平均值±标准差）。19名正常对照者的β-NAH水平为15.8±3.5 U/l（平均值±标准差）。肝转移患者的β-NAH也显著升高（36.9±20.1 U/l）。在25例有肝外转移的癌症患者中，β-NAH水平（18.3±5.2）与对照组相比无显著升高。它作为非CEA产生性肝转移的标志物具有潜在价值。
